For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $12.79 in the prior trading day, Ginkgo Bioworks Holdings Inc (NYSE: DNA) closed at $11.59, down -9.38%. In other words, the price has decreased by -$9.38 from its previous closing price. On the day, 1.43 million shares were traded. DNA stock price reached its highest trading level at $12.4465 during the session, while it also had its lowest trading level at $11.555.
Ratios:
Our goal is to gain a better understanding of DNA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.41 and its Current Ratio is at 5.41. In the meantime, Its Debt-to-Equity ratio is 0.70 whereas as Long-Term Debt/Eq ratio is at 0.70.
Raymond James Downgraded its Outperform to Mkt Perform on November 14, 2023, whereas the target price for the stock was revised from $3.50 to $2.50.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 17 ’25 when Coen Steven P. sold 1,312 shares for $13.65 per share. The transaction valued at 17,907 led to the insider holds 6,738 shares of the business.
Coen Steven P. bought 5,609 shares of DNA for $84,135 on Oct 21 ’25. On Oct 21 ’25, another insider, Coen Steven P., who serves as the Officer of the company, bought 1,312 shares for $13.65 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNA now has a Market Capitalization of 686125120 and an Enterprise Value of 597515648. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.97 while its Price-to-Book (P/B) ratio in mrq is 0.99. Its current Enterprise Value per Revenue stands at 2.589 whereas that against EBITDA is -2.589.
Stock Price History:
The Beta on a monthly basis for DNA is 1.53, which has changed by 0.53910947 over the last 52 weeks, in comparison to a change of 0.15566266 over the same period for the S&P500. Over the past 52 weeks, DNA has reached a high of $17.58, while it has fallen to a 52-week low of $5.00. The 50-Day Moving Average of the stock is -8.86%, while the 200-Day Moving Average is calculated to be 10.86%.
Shares Statistics:
The stock has traded on average 1.60M shares per day over the past 3-months and 1129040 shares per day over the last 10 days, according to various share statistics. A total of 43.82M shares are outstanding, with a floating share count of 40.53M. Insiders hold about 27.88% of the company’s shares, while institutions hold 62.04% stake in the company. Shares short for DNA as of 1760486400 were 6651827 with a Short Ratio of 4.16, compared to 1757894400 on 6273158. Therefore, it implies a Short% of Shares Outstanding of 6651827 and a Short% of Float of 14.499999999999998.
Earnings Estimates
. The current market rating for Ginkgo Bioworks Holdings Inc (DNA) reflects the collective analysis of 3.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$1.27, with high estimates of -$1.17 and low estimates of -$1.36.
Analysts are recommending an EPS of between -$5.16 and -$5.33 for the fiscal current year, implying an average EPS of -$5.25. EPS for the following year is -$4.34, with 3.0 analysts recommending between -$3.51 and -$4.85.
Revenue Estimates
4 analysts predict $38.95M in revenue for. The current quarter. It ranges from a high estimate of $40M to a low estimate of $37.5M. As of. The current estimate, Ginkgo Bioworks Holdings Inc’s year-ago sales were $89.05MFor the next quarter, 4 analysts are estimating revenue of $40.19M. There is a high estimate of $43.7M for the next quarter, whereas the lowest estimate is $37.08M.
A total of 4 analysts have provided revenue estimates for DNA’s current fiscal year. The highest revenue estimate was $181M, while the lowest revenue estimate was $175M, resulting in an average revenue estimate of $177.07M. In the same quarter a year ago, actual revenue was $227.04MBased on 4 analysts’ estimates, the company’s revenue will be $202.55M in the next fiscal year. The high estimate is $210M and the low estimate is $194.9M.
